B. Metzler seel. Sohn & Co. AG Decreases Stake in Insulet Corporation $PODD

Key Points

• B. Metzler seel. Sohn & Co. AG significantly reduced its stake in Insulet Corporation by 64.6%, selling 6,763 shares and now holding 3,713 shares worth approximately $975,000.
• Insulet's revenue for the recent quarter rose by 32.9% year-over-year, hitting $649.10 million, and the company reported earnings per share of $1.17, surpassing analysts' expectations.
• Analysts have given Insulet a consensus rating of "Moderate Buy" with a target price averaging $332.71, reflecting positive sentiment as multiple firms have raised their price targets on the stock.

B. Metzler seel. Sohn & Co. AG reduced its holdings in Insulet Corporation (NASDAQ:PODD - Free Report) by 64.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,713 shares of the medical instruments supplier's stock after selling 6,763 shares during the period. B. Metzler seel. Sohn & Co. AG's holdings in Insulet were worth $975,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Brooklyn Investment Group boosted its holdings in shares of Insulet by 7.0% in the 1st quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier's stock valued at $209,000 after acquiring an additional 52 shares during the last quarter. OLD National Bancorp IN boosted its position in Insulet by 6.7% during the first quarter. OLD National Bancorp IN now owns 880 shares of the medical instruments supplier's stock worth $231,000 after purchasing an additional 55 shares in the last quarter. Cooper Financial Group lifted its position in shares of Insulet by 5.7% in the first quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier's stock valued at $283,000 after acquiring an additional 58 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its position in shares of Insulet by 23.1% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 314 shares of the medical instruments supplier's stock valued at $82,000 after acquiring an additional 59 shares in the last quarter. Finally, HighTower Advisors LLC lifted its stake in shares of Insulet by 2.1% in the first quarter. HighTower Advisors LLC now owns 2,882 shares of the medical instruments supplier's stock worth $757,000 after buying an additional 60 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on PODD shares. Jefferies Financial Group reaffirmed a "buy" rating on shares of Insulet in a research note on Thursday, August 7th. Citigroup reiterated a "buy" rating on shares of Insulet in a report on Tuesday, July 8th. Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Wall Street Zen upgraded Insulet from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Finally, The Goldman Sachs Group initiated coverage on shares of Insulet in a research report on Friday, May 30th. They issued a "buy" rating and a $380.00 price objective on the stock. Sixteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, Insulet has a consensus rating of "Moderate Buy" and an average price target of $332.71.

Insulet Stock Performance

Insulet stock traded up $2.83 during midday trading on Thursday, hitting $346.36. 230,311 shares of the company's stock were exchanged, compared to its average volume of 753,441. Insulet Corporation has a 12-month low of $211.27 and a 12-month high of $350.00. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The stock has a market cap of $24.38 billion, a price-to-earnings ratio of 105.28, a price-to-earnings-growth ratio of 2.85 and a beta of 1.36. The firm's 50 day simple moving average is $306.11 and its 200 day simple moving average is $288.90.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. During the same period last year, the business posted $0.55 EPS. The company's revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts predict that Insulet Corporation will post 3.92 EPS for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.